Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC

This is a prospective, open-label, single-center, single-arm phase II clinical trial evaluating the efficacy and safety of multimodal ablation in combination with perioperative tislelizumab and chemotherapy in patients with pathologically confirmed resectable stage II-IIIB (N2) non-small cell lung cancer (NSCLC).

NCT Number	NCT07729670
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	NSCLC
Enrollment	42 participants
Start Date	2026-06
Primary Completion	2029-06 (estimated)
Study Completion	2031-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-27